Dulaglutide: Research, Dosing, and Where to Buy in 2026
A research-first profile for Dulaglutide, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Dulaglutide is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 14 PubMed-cited papers, and 2 attributed expert mentions for Dulaglutide, each linked to its source.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 14 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as fda_approved.
What is Dulaglutide?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 1 cited mention
"refeeding pretty hard on dual glutide, simlutite, tepidite and redutite is difficult because it has such a long halflife."
How does Dulaglutide work?
Experts on mechanism · 1 cited mention
"you have semaglutide, liraglutide, dulaglutide, single receptor agonist on the GLP-1."
What is Dulaglutide researched for?
Early-generation single GLP-1 receptor agonist in the same class as semaglutide/liraglutide.
Dulaglutide Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Dulaglutide in 2026
No tracked vendor recommendations for Dulaglutide yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Dulaglutide. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“refeeding pretty hard on dual glutide, simlutite, tepidite and redutite is difficult because it has such a long halflife.”
See 1 more expert mention →
-
“you have semaglutide, liraglutide, dulaglutide, single receptor agonist on the GLP-1.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Dulaglutide. Each line links to the original source.
- "Consistent with this, pharmacodynamic analysis demonstrated that intraintestinal dulaglutide-DNP administration significantly reduced blood glucose levels to 39.0 % of the baseline, corresponding to a pharmacological availability of 15.7 % relative to intravenous dulaglutide-DNP administration." · Chikamatsu S et al, 2026 PubMed
- "Rates of super responders were highest for Zepbound (34%), followed by Wegovy (26%), Mounjaro (24%), and Ozempic (10%)." · Venkatakrishnan AJ et al, 2026 PubMed
- "Compared with patients with minimal or moderate response, super responders were more likely to be younger (mean age 51 years versus 55 years), female (80% versus 58%-65%), and white (90% versus 80%)." · Venkatakrishnan AJ et al, 2026 PubMed
- "Finally, the SMART-DECISION trial suggested that discontinuation of beta-blockers in stable patients one year after myocardial infarction with an LVEF of at least 40% may be safe and noninferior to continuation." · Abdul Jabbar AB et al, 2026 PubMed
- "**RESULTS**: Overall, 29.7% of patients switched at least once and 14.3% switched two or more times." · Łupina K et al, 2026 PubMed
- "Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight-reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D." · Pearson MJ et al, 2026 PubMed
- "Effect estimates were reported as odds ratios (ORs) with 95% confidence intervals (CIs), with statistical significance defined as P < .05." · Nanah MH et al, 2026 PubMed
- "They also had higher rates of comorbidities, including diabetes (64.3% vs 31.5%), chronic kidney disease (19.6% vs 14.1%), and nicotine dependence (20.4% vs 19.1%), but lower rates of alcohol use disorder (2.3% vs 4.6%), compared with the BS group." · Nanah MH et al, 2026 PubMed
- "Initiation of advanced IBD therapies was also lower in the GLP-1 RA group (OR 0.45, 95% CI, 0.33-0.61; P < .0001)." · Nanah MH et al, 2026 PubMed
- "Participants aged 40 years or older with type 2 diabetes and atherosclerotic cardiovascular disease, HbA1c between 7% and 10·5%, and a BMI of 25 kg/m2 or greater were randomly assigned 1:1 to once-weekly blinded subcutaneous injection of either tirzepatide up to 15 mg or dulaglutide 1·5 mg." · Zoungas S et al, 2026 PubMed
Research and Studies
14 PubMed-indexed papers reference Dulaglutide. Top 14 shown.
Legal Status
Dulaglutide is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Dulaglutide FDA-approved?
Dulaglutide is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Dulaglutide?
14 PubMed-indexed paper(s) reference Dulaglutide in our current research feed. See the Research and Studies section above for citations.